Latest Content

HR+/HER2- Metastatic Breast Cancer Progression Improved With Sac-TMT

October 19th 2025, 1:25am

By Andrea Eleazar, MHS

Article

Sac-TMT improved progression-free survival in patients with HR+/HER2– breast cancer.

Presurgical Enhertu Combo Elicits Response Benefit in HER2+ Early Breast Cancer

October 19th 2025, 12:28am

By Chris Ryan

Article

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early breast cancer.

Similar Incidence of Second Primary Tumors After Libtayo or Placebo for CSCC

October 18th 2025, 11:32pm

By Jax DiEugenio

Article

Postsurgical Libtayo and placebo showed similar rates of second primary tumors in high-risk CSCC

Enhertu Reduces Risk of Invasive Disease or Death in HER2+ Breast Cancer

October 18th 2025, 10:49pm

By Ashling Wahner

Article

Enhertu led to a 53% reduction in the risk of invasive disease or death versus Kadcyla in some patients with high-risk, HER2-positive breast cancer.

Postsurgical Opdivo Associated With Long-Term Activity in Melanoma

October 18th 2025, 9:26pm

By Kyle Doherty

Article

Adjuvant Opdivo significantly extended relapse-free survival in patients with resected stage advanced melanoma.

Keytruda Combo Improves Progression, Survival in Recurrent Ovarian Cancer

October 18th 2025, 8:16pm

By Tim Cortese

Article

Clinical trial results showed favorable results with Keytruda-based therapy in this ovarian cancer population.

Imdelltra Improves Survival For Some With Small Cell Lung Cancer

October 18th 2025, 7:08pm

By Russ Conroy

Article

Clinical trial data support the use of Imdelltra as a standard of care for all patients with second-line small cell lung cancer.

Lymphoma Survivors Find Fatigue Relief From Multidisciplinary Intervention

October 18th 2025, 6:29pm

By Alex Biese

Article

Lymphoma survivors with chronic fatigue participating in a multidisciplinary intervention program experienced benefits to fatigue and quality of life.

Younger Female Patients With Cancer Report Less Emotional Function

October 18th 2025, 5:46pm

By Bridget Hoyt

Article

Among patients with solid tumors, baseline emotional functioning was moderate, with lower functioning for female and younger patients.

Imdelltra Plus Chemoimmunotherapy Safely Elicits Responses in ES-SCLC

October 18th 2025, 4:39pm

By Gina Mauro

Article

In patients with extensive-stage small cell lung cancer Imdelltra plus chemoimmunotherapy was associated with positive outcomes.

Giredestrant/Afinitor Reduces Progression in Advanced Breast Cancer

October 18th 2025, 2:17pm

By Silas Inman

Article

In patients with ER-positive, HER2-negative advanced breast cancer, giredestrant and Afinitor reduced risk of disease progression or death.

Tagrisso Plus Chemo Offers Survival benefit in EGFR+ NSCLC

October 17th 2025, 11:52pm

By Chris Ryan

Article

Among patients with EGFR-mutated non-small cell lung cancer Tagrisso plus chemotherapy was associated with an improvement in survival.

Quality of Life Maintained with Akeega Combo in Prostate Cancer

October 17th 2025, 9:28pm

By Bridget Hoyt

Article

For patients with HRRm prostate cancer receiving Akeega with prednisone, quality of life remained at baseline.

Open-Label Extension of Ponsegromab Shows Efficacy in Cancer-Associated Cachexia

October 17th 2025, 8:47pm

By Ryan Scott

Article

Ponsegromab improved body weight, suppressed GDF-15 and was well-tolerated over 64 weeks in cancer-associated cachexia, including patients switching from placebo.

Kisqali Plus Aromatase Inhibitor Shows Long-Term Benefit in Early Breast Cancer

October 17th 2025, 8:30pm

By Kyle Doherty

Article

Adding Kisqali to a nonsteroidal aromatase inhibitor continued to reduce recurrence risk and improve survival at five years in early breast cancer.